Cargando…
Cystic fibrosis presentation in del. F508 and p. Tyr109Glyfs compound heterozygote CFTR state: a case report
The diagnosis of cystic fibrosis (CF) is commonly confirmed by molecular genetics with the presence of specific mutations of cystic fibrosis transmembrane conductance regulator (CFTR) gene. We report a case of cystic fibrosis (CF) in a 15-year-old female patient who is a compound heterozygote for CF...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Croatian Medical Schools
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6563179/ https://www.ncbi.nlm.nih.gov/pubmed/31187952 http://dx.doi.org/10.3325//cmj.2019.60.246 |
_version_ | 1783426490748108800 |
---|---|
author | Turkalj, Mirjana Matišić, Vid Šimić, Arijana Juginović, Alen Erceg, Damir Drinković, Dorian Tješić Höppner, Wolfgang Primorac, Dragan |
author_facet | Turkalj, Mirjana Matišić, Vid Šimić, Arijana Juginović, Alen Erceg, Damir Drinković, Dorian Tješić Höppner, Wolfgang Primorac, Dragan |
author_sort | Turkalj, Mirjana |
collection | PubMed |
description | The diagnosis of cystic fibrosis (CF) is commonly confirmed by molecular genetics with the presence of specific mutations of cystic fibrosis transmembrane conductance regulator (CFTR) gene. We report a case of cystic fibrosis (CF) in a 15-year-old female patient who is a compound heterozygote for CFTR gene, with delta F508 and Tyr109Glyfs mutations detected. This is the first detailed description of such a case in the medical literature. The primary CF presentation occurred at the age of 9 in the form of gastrointestinal symptoms including greasy, bulky, and foul-smelling stool. The patient exhibited delayed growth, with her height and weight being below the 5th centile for age according to the World Health Organization growth curves. Pancreatic enzyme supplement treatment was started immediately, alongside high-fat and high-calorie diet, resulting in patient’s recovery and development. DNA analysis of CFTR gene demonstrated the presence of del. F508 mutation and a rare combining deletion and insertion mutation p. Tyr109Glyfs. The combination of the two mutations is very rare in CF patients and is therefore valuable to document this case in order to provide information on disease progression, therapy options, and outcomes. With standard treatment and early diagnosis, the patient is currently doing well and is not restricted by the disease in her daily and sports activities. |
format | Online Article Text |
id | pubmed-6563179 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Croatian Medical Schools |
record_format | MEDLINE/PubMed |
spelling | pubmed-65631792019-06-20 Cystic fibrosis presentation in del. F508 and p. Tyr109Glyfs compound heterozygote CFTR state: a case report Turkalj, Mirjana Matišić, Vid Šimić, Arijana Juginović, Alen Erceg, Damir Drinković, Dorian Tješić Höppner, Wolfgang Primorac, Dragan Croat Med J 11th ISABS CONFERENCE The diagnosis of cystic fibrosis (CF) is commonly confirmed by molecular genetics with the presence of specific mutations of cystic fibrosis transmembrane conductance regulator (CFTR) gene. We report a case of cystic fibrosis (CF) in a 15-year-old female patient who is a compound heterozygote for CFTR gene, with delta F508 and Tyr109Glyfs mutations detected. This is the first detailed description of such a case in the medical literature. The primary CF presentation occurred at the age of 9 in the form of gastrointestinal symptoms including greasy, bulky, and foul-smelling stool. The patient exhibited delayed growth, with her height and weight being below the 5th centile for age according to the World Health Organization growth curves. Pancreatic enzyme supplement treatment was started immediately, alongside high-fat and high-calorie diet, resulting in patient’s recovery and development. DNA analysis of CFTR gene demonstrated the presence of del. F508 mutation and a rare combining deletion and insertion mutation p. Tyr109Glyfs. The combination of the two mutations is very rare in CF patients and is therefore valuable to document this case in order to provide information on disease progression, therapy options, and outcomes. With standard treatment and early diagnosis, the patient is currently doing well and is not restricted by the disease in her daily and sports activities. Croatian Medical Schools 2019-06 /pmc/articles/PMC6563179/ /pubmed/31187952 http://dx.doi.org/10.3325//cmj.2019.60.246 Text en Copyright © 2019 by the Croatian Medical Journal. All rights reserved. http://creativecommons.org/licenses/by/2.5/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | 11th ISABS CONFERENCE Turkalj, Mirjana Matišić, Vid Šimić, Arijana Juginović, Alen Erceg, Damir Drinković, Dorian Tješić Höppner, Wolfgang Primorac, Dragan Cystic fibrosis presentation in del. F508 and p. Tyr109Glyfs compound heterozygote CFTR state: a case report |
title | Cystic fibrosis presentation in del. F508 and p. Tyr109Glyfs compound heterozygote CFTR state: a case report |
title_full | Cystic fibrosis presentation in del. F508 and p. Tyr109Glyfs compound heterozygote CFTR state: a case report |
title_fullStr | Cystic fibrosis presentation in del. F508 and p. Tyr109Glyfs compound heterozygote CFTR state: a case report |
title_full_unstemmed | Cystic fibrosis presentation in del. F508 and p. Tyr109Glyfs compound heterozygote CFTR state: a case report |
title_short | Cystic fibrosis presentation in del. F508 and p. Tyr109Glyfs compound heterozygote CFTR state: a case report |
title_sort | cystic fibrosis presentation in del. f508 and p. tyr109glyfs compound heterozygote cftr state: a case report |
topic | 11th ISABS CONFERENCE |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6563179/ https://www.ncbi.nlm.nih.gov/pubmed/31187952 http://dx.doi.org/10.3325//cmj.2019.60.246 |
work_keys_str_mv | AT turkaljmirjana cysticfibrosispresentationindelf508andptyr109glyfscompoundheterozygotecftrstateacasereport AT matisicvid cysticfibrosispresentationindelf508andptyr109glyfscompoundheterozygotecftrstateacasereport AT simicarijana cysticfibrosispresentationindelf508andptyr109glyfscompoundheterozygotecftrstateacasereport AT juginovicalen cysticfibrosispresentationindelf508andptyr109glyfscompoundheterozygotecftrstateacasereport AT ercegdamir cysticfibrosispresentationindelf508andptyr109glyfscompoundheterozygotecftrstateacasereport AT drinkovicdoriantjesic cysticfibrosispresentationindelf508andptyr109glyfscompoundheterozygotecftrstateacasereport AT hoppnerwolfgang cysticfibrosispresentationindelf508andptyr109glyfscompoundheterozygotecftrstateacasereport AT primoracdragan cysticfibrosispresentationindelf508andptyr109glyfscompoundheterozygotecftrstateacasereport |